Clinical Trial · NCT02970786

Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans

Overview

The primary objective of the trial is to test the new radio tracer 68Ga-NODAGA-E\[c(RGDyK)\]2 for PET imaging of angiogenesis. The tracer has the potential of identifying tumors with a high level of angiogenesis, which is one of the cancer hallmarks. Furthermore, the tracer can potentially be used in early response assessment to anti-angiogenic treatment. This is a first-in-man study to test the radio tracer in cancer patients. Safety, biodistribution and dosimetry will be evaluated by repeated PET imaging (10 minutes, 1 hour and 2 hours post injection).

Sponsor

National University Hospital, Singapore

Phase

Phase 1

Contacts

Malene M Clausen, MD, PhD (CONTACT)

malene.martini.clausen@regionh.dk

+4522524536

Andreas Kjaer, Professor (CONTACT)

andreas.kjaer@regionh.dk

+4535454011

ClinicalTrials.gov

NCT02970786

Drug / Compound

NODAGA-E(c[RGDyK])2

Isotope(s):

Target(s):

αvβ3

Ligand Class: Peptides

Chelator: NODAGA

Linker: E

Eligibility

Inclusion

Diagnosed with neuroendocrine cancer, breast cancer or ovarian cancer

Exclusion

Exclusion criteria not yet provided.